Search

Your search keyword '"Valentino, Leonard A."' showing total 248 results

Search Constraints

Start Over You searched for: Author "Valentino, Leonard A." Remove constraint Author: "Valentino, Leonard A."
248 results on '"Valentino, Leonard A."'

Search Results

201. Defining the Impact of Social Drivers on Health Outcomes for People with Inherited Bleeding Disorders.

203. Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B.

204. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia.

205. Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia.

206. Contributors

207. A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results.

208. Women and girls' participation in haemophilia clinical trials.

209. Joint health and pain in the changing hemophilia treatment landscape.

210. Race and ethnicity reporting and representation in hemophilia clinical trials.

212. A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?

213. Hemophilia gene therapy: first, do no harm.

214. A commentary on "maladaptive lymphangiogenesis" according to Newton's third law: the law of action and reaction as it applies to joint bleeding.

216. The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary.

218. Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community.

219. Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States.

220. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years.

221. Building the blueprint: Formulating a community-generated national plan for future research in inherited bleeding disorders.

222. Return to Sport Activities and Risk of Reinjury Following Primary Anterior Cruciate Ligament Reconstruction.

223. Big picture initiatives in bleeding disorders.

225. Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders.

226. The intersection of vector biology, gene therapy, and hemophilia.

227. Discussing investigational AAV gene therapy with hemophilia patients: A guide.

228. The role of telemedicine in the delivery of health care in the COVID-19 pandemic.

229. Prophylaxis for hemophilia A without inhibitors: treatment options and considerations.

230. The Role of Gene Therapy in Cartilage Repair.

231. Increased bone resorption in hemophilia.

232. Issues complicating precision dosing for factor VIII prophylaxis.

233. Joint lavage followed by intra-articular injection of hyaluronic acid and/or corticosteroids in patients with severe hemophilic arthropathy of the knee: Is this intervention really effective?

234. Individualizing prophylaxis in hemophilia: a review.

235. The role of Rixubis™ in the treatment of hemophilia B.

236. Management of joint bleeding in hemophilia.

237. Venous access in the management of hemophilia.

238. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.

239. Recombinant activated factor VII as a temporary reversal agent for warfarin anticoagulation: a cautionary report on an off-label application.

240. Arteriovenous fistula for long-term venous access for boys with hemophilia.

241. Blood safety and the choice of anti-hemophilic factor concentrate.

242. Managing the pediatric patient and the adolescent/adult transition.

243. Future aspects of hemophilia research and care.

244. Gangliosides promote platelet adhesion and facilitate neuroblastoma cell adhesion under dynamic conditions simulating blood flow.

245. Central venous access devices in patients with hemophilia.

246. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene.

247. Gangliosides regulate tumor cell adhesion to collagen.

248. c-myc proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramide.

Catalog

Books, media, physical & digital resources